Ignite Creation Date:
2024-05-06 @ 1:37 AM
Last Modification Date:
2024-10-26 @ 11:07 AM
Study NCT ID:
NCT01857232
Status:
COMPLETED
Last Update Posted:
2020-11-25
First Post:
2013-05-16
Brief Title:
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
Sponsor:
Acacia Pharma Ltd
Organization:
Acacia Pharma Ltd
Study Overview
Official Title:
Randomised Double-blind Dose-finding Phase II Study to Assess the Efficacy of APD403 in the Prevention of Nausea and Vomiting Caused by Cisplatin- or AnthracyclineCyclophosphamide AC-Based Chemotherapy
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None